South San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Escape Bio is raising $73,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Julie Smith played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Escape Bio

ESCAPE Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of precision small molecule therapies to treat genetically defined subpopulations in neurodegenerative diseases. We believe that developing therapies precisely targeted towards a perturbed pathway or genetic variant will ultimately address the root cause of disease, thereby potentially improving probability of success compared to less-selective approaches or those that target downstream manifestations of disease.

To learn more about Escape Bio, visit http://www.escapebio.com/

Contact:
Julie Smith, President and Chief Executive Officer
650-431-0100
https://www.linkedin.com/in/julie-anne-smith-87a1778/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved